JAZZ vs. AXSM, RPRX, CORT, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIX
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Axsome Therapeutics (AXSM), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "medical" sector.
Jazz Pharmaceuticals vs. Its Competitors
Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 22.4% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Axsome Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.
Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of -9.91% compared to Axsome Therapeutics' net margin of -49.88%. Jazz Pharmaceuticals' return on equity of 5.02% beat Axsome Therapeutics' return on equity.
In the previous week, Axsome Therapeutics had 16 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 40 mentions for Axsome Therapeutics and 24 mentions for Jazz Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.44 beat Jazz Pharmaceuticals' score of 0.39 indicating that Axsome Therapeutics is being referred to more favorably in the media.
Axsome Therapeutics presently has a consensus target price of $178.00, indicating a potential upside of 69.15%. Jazz Pharmaceuticals has a consensus target price of $181.43, indicating a potential upside of 60.09%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.
Summary
Axsome Therapeutics beats Jazz Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:JAZZ) was last updated on 8/13/2025 by MarketBeat.com Staff
MarketBeat All Access